NTBL Notable Labs Ltd: מכפיל מחיר להכנסות עתידי
High barriers to entry for Notable Labs, Ltd. (NTBL) are driven by R&D costs and stringent FDA oversight. The forward P/S multiple helps assess market expectations, where 7.70 reflects the most recent value of the metric. Business efficiency relies on the express delivery of biosamples, while growth potential is based on increasing clinic demand for predictive diagnostics in oncology.
Notable Labs Corp (NTBL) - פילוחי מדדים ודוחות פיננסיים
AI-driven screening of live cells for oncology therapy selection by Notable Labs, Ltd. (NTBL) creates significant value, which is reflected in the expected price-to-sales ratio. This indicator compares current market capitalization with projected sales volume, allowing investors to instantly determine the extent of the business's market discount or premium relative to competitors while assessing the stability of the cost of capital over time.
